Nexvet Biopharma plc (NASDAQ: NVET) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Nexvet Biopharma plc and Ritter Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Nexvet Biopharma plc||N/A||N/A||N/A||($1.75)||-3.84|
|Ritter Pharmaceuticals||N/A||N/A||-$18.38 million||($1.16)||-0.30|
This is a summary of current ratings and recommmendations for Nexvet Biopharma plc and Ritter Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nexvet Biopharma plc||0||1||0||0||2.00|
Nexvet Biopharma plc presently has a consensus price target of $6.72, indicating a potential upside of 0.00%. Ritter Pharmaceuticals has a consensus price target of $3.40, indicating a potential upside of 871.43%. Given Ritter Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Ritter Pharmaceuticals is more favorable than Nexvet Biopharma plc.
This table compares Nexvet Biopharma plc and Ritter Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nexvet Biopharma plc||N/A||-102.72%||-89.82%|
Institutional and Insider Ownership
48.4% of Nexvet Biopharma plc shares are owned by institutional investors. Comparatively, 2.2% of Ritter Pharmaceuticals shares are owned by institutional investors. 37.0% of Nexvet Biopharma plc shares are owned by company insiders. Comparatively, 30.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Nexvet Biopharma plc Company Profile
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
Receive News & Ratings for Nexvet Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.